


FIG. 1A

Preliminary PK Parameters Geometric Mean (%CV)**
Cycle 1 Dose 1

	Half-life (Days)	Cmax (ug/mL)	AUC_{0-14d} (Day*ug/mL)
100 mg (n=2)	10.7 (10)	32 (15)	181 (22)
200 mg (n=2)	8.5 (19)	50 (4.3)	294 (18)
400 mg (n=2)	9.6 (62)	173 (11)	974 (37)
800 mg (n=7)	8.8 (33)	239 (14)	1517 (19)*
1600 mg (n=3)	11.8 (13)	513 (15)	3316 (7.5)

*N=6, ** PK Analysis Based on Nominal Time
Initial Approach to Administration is Stepwise IV Infusion, Starting with 50mg/hr (30 mins), Incrementally Increased (<=2-fold), Maximal Rate of 400mg/hr.

FIG. 1B



Serum
BCMA+ Cells
Test
0% Bound Control
100% Bound Control (Spiked SEA-BCMA)
1.Bind
2.Detect
BCMA
SEA-BCMA (Serum or Spike)
SEA-BCMA+ Fluorophore

FIG. 2A




Standard Curve: SEA-BCMA Spiked in Serum, Plasma and PBS
Percent Occupancy
100%
80%
60%
40%
20%
0%
no Ab
0.01
0.1
1
10
100
[SEA-BCMA] µg/ml
PBS
Plasma
Serum
Clinical Run2-serum

FIG. 2B



*PK exposure for this patient is in the range of patients treated at 800 mg due to low body weight

FIG. 3A



SEA-BCMA/BCMA Receptor Binding Capacity
800 MG Cohort
Percent Receptor Bound
100%
80%
60%
40%
20%
0%
0
10
20
30
Days from first dose
200ug/ml
12.5ug/ml
1.6ug/ml
0.4ug/ml
0.2ug/ml
0.1ug/ml
0.05ug/ml
Titration of SEA-BCMA
Patients dosed at 800 mg
10003-0007
10002-0008
10004-0009
10003-0010
10003-0011
10004-0012
10003-0013

FIG. 3B



SEA-BCMA/BCMA Receptor Binding Capacity
1600 MG Cohort
Percent Receptor Bound
100%
80%
60%
40%
20%
0%
0
10
20
30
Days from First Dose
200ug/ml
12.5ug/ml
1.6ug/ml
0.4ug/ml
0.2ug/ml
Titration of SEA-BCMA
Patients Dosed at 1600 mg
10003-0007
10003-0015
10003-0016
10003-0017
10007-0018
10004-0019
10004-0020

FIG. 3C



Unbound BCMA on Malignant Plasma Cells
BSLN
C2D22
MFI by FACS
30,000
20,000
10,000
2,000
1,500
1,000
500
0
Patient 1
Patient 2
Patient 3
Patient 4
Patient 5
Patients dosed at 800mg
Patients dosed at 1600mg

FIG. 4

Regimen	Therapy	Best Response	Duration
1	Bortezomib / Dex	SD	3 mos.
2	Cyclophosphamide / Bortezomib / Dex	PD	1 mo.
3	Carfilzomib / Lenalidomide / Dex; Kd maintenance	CR	35 mos.
4	Carfilzomib / Lenalidomide / Dex	NE (off for AE)	1.5 mos.
5	Isatuximab	NE (off for AE)	1 mo.
6	Daratumumab / Dex	NE (off for AE)	1 mo.
7	Carfilzomib / Pomalidimide/ Dex	MR	8 mos.
8	**SEA-BCMA**	**VGPR**	**2+ mo**

FIG. 5



Involved sFLC (mg/dL)
600
550
500
450
400
350
300
250
200
150
100
50
0
-5
0
5
10
15
20
25
30
35
40
Days from C1D01
upper range of healthy individuals
Patient received 7 lines of therapy prior to SEA-BCMA treatment at 1600 mg

FIG. 6A



Total Membrane BCMA on Plasma Cells at Baseline
(Measured by Flow Cytometry)
Total Membrane BCMA
(Signal Above Background)
8000
6000
4000
2000
0
Patient 1
Patient 2
Patient 3
Patient 4
Patient 5
Patient 6
Evaluable Subjects

FIG. 6B

Regimen	Therapy	Best Response	Duration
1	Thalidomide / Dex	PD	1 mo.
2	Bortezomib / Dex	VGPR	Unknown
3	Lenalidomide / Dex; Len Maintenance	VGPR	Unknown
4	Carfilzomib	PR	15 mos.
5	Carfilzomib / Dex	PR	9 mos.
6	Carfilzomib / Pomalidomide / Dex	MR	7 mos.
7	Elotuzumab/ Lenalidomide / Dex	PR	16 mos.
8	Daratumumab	SD	4 mos.
9	**SEA-BCMA**	**SD**	**10+ mos.**

FIG. 7




FIG. 8A




FIG. 8B




FIG. 8C




FIG. 8D



SEA-BCMA
SEA-BCMA/Nirogacestat
hIgG1k
hIgG1k/Nirogacestat
% of Maximun lysis
40
20
10
0.0001
0.01
1
100
10000
SEA-BCMA ng/ml

FIG. 9B



Cell Count
100
80
60
40
20
0
10^0 10^1 10^2 10^3 10^4 10^5 10^6
Fluorescence

FIG. 9A



NFkB p65 Activation (RLU)
5x10^6
4x10^6
3x10^6
2x10^6
1x10^6
0
Baseline
GSI
APRIL
SEA-BCMA

FIG. 10



Untreated
SEA-control
SEA-BCMA
Daratumumab
SEA-control + Daratumumab
SEA-BCMA + Daratumumab
Naive Control
Daratumumab Weekly for 5 weeks 1 mg/kg
SEA-BCMA Once 3mg/kg
SEA-control Once 3mg/kg
Mean Luminescence (Photons/sec)
10^{10}
10^{9}
10^{8}
10^{7}
10^{6}
10^{5}
0
20
40
60
80
100
Days Post Implant

FIG. 11




FIG. 12A




FIG. 12B